Back to Anacor Homepage Developing Drug Candidates Through Boron Chemistry
Infinite Menus, Copyright 2006, OpenCube Inc. All Rights Reserved.
Overview | Press Releases | Publications | Contact Us | Scientific Presentations
    News and Events - Scientific Presentations

We are a biopharmaceutical company developing small molecule therapeutics derived from our boron chemistry platform
Learn more about Tavaborole
Learn more about AN2728
Learn more about GSK 052
Date  

Presentations
October 23-27, 2011
Washington, DC

American Association of Pharmaceutical Sciences Annual Meeting
 

Pre-formulation of GSK2251052, A Novel Boron-Containing Small Molecule Designed with Ideal CMC Properties and In Development for the Treatment of Serious Gram Negative Bacterial Infections

Development of a Lyophilization Cycle for the Manufacture of a Phase I Intravenous Formulation of the Novel Boron-Containing Antibacterial Agent GSK2251052
October 16-20, 2011
Atlanta, Georgia

International Society for the Study of Xenobiotics
 

Metabolic Fate and Disposition of GSK2251052, a Novel Boron-Based Antimicrobial against Gram-Negative Bacteria, in Sprague Dawley Rats and Cynomolgus Monkeys
September 17-20, 2011
Chicago, IL

51st ICAAC
 

Novel Boron-containing Aminoacyl-tRNA Synthetase Inhibitors with Gram-negative Bacterial Activity

Use of a Population Pharmacokinetic Model for Dose Selection in Phase IIb Studies for GSK2251052

Dose Ranging Studies with the LeuRS Inhibitor GSK2251052 against Escherichia coli in a Mouse Thigh Suture Infection Model

Susceptibility Testing of a Novel Mechanism Antibacterial GSK2251052 against Category A/B Bacterial Biothreat Agents

A Comparison of Broth Microdilution, Macrodilution and Agar Dilution for GSK2251052 and Meropenem against Gram-negative Organisms and B. fragilis

Comparative In Vitro Activity of GSK2251052, a Novel Boron Leucyl-tRNA Synthetase Inhibitor, Against 916 Anaerobic Organisms

GSK2251052, a Novel Boron-containing Protein Synthesis Inhibitor, with Comparative in vitro Activity against Pseudomonas aeruginosa from a Global Population
September 7-10, 2011
Barcelona, Spain

41st Annual Meeting of the European Society for Dermatological Research
 

2-Year Carcinogenicity Studies Demonstrates that AN2690, a Novel Boron-containing Small Molecule for Topical Treatment of Onychomycosis, is Considered Noncarcinogenic

Preclinical Safety Studies with AN2690, a Novel Boron-containing Small Molecule for Topical Treatment of Onychomycosis, Demonstrate Promising Safety Profile

Comparative In Vivo Biotransformation of 14C-AN2690 in Mouse, Rat and Human Following Topical or Oral Administration

Safety, Tolerability and Pharmacokinetics of AN2728 Ointment, a Potential Boron-based Treatment for Psoriasis

Safety and Efficacy of AN2728 Ointment in a 12-week, Randomized, Double-Blind, Vehicle-Controlled, Bilateral Trial for the Treatment of Psoriasis

Dermal Tolerability and Preliminary Efficacy of AN2728 and AN2898, Novel Boron-Based Small Molecules, in the Treatment of Psoriasis
May 7, 2011
Milan, Italy

21st European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
 

Safety, tolerability, and pharmacokinetics of a novel Gram-negative antimicrobial, GSK2251052 (GSK '052), in healthy subjects

Interspecies scaling for prediction of human intravenous pharmacokinetics of GSK2251052 (GSK '052), a novel boron-based antimicrobial against Gram-negative bacteria
May 5, 2011
Phoenix, AZ

71st SID Annual Meeting
 

Safety and Efficacy of AN2728 Ointment in a Phase 2b Dose- Ranging, Bilateral Study of Mild-to-Moderate Plaque Psoriasis
April 12, 2011

Resistance is Futile: the Challenge of Antibacterial Drug Development" Conference Hosted by Drug Discovery Chemistry
 

Tackling Microbial Resistance: Novel Targets Accessed by Boron Antibacterials
November 14-18, 2010
New Orleans, LA

AAPS Annual Meeting
 

High Throughput LC/MS/MS Determination of AN3365, A Novel Boron-Containing Compound in Various Biological Matrices to Support Non-GLP
November 3-7, 2010
Atlanta, GA

ASTMH 59th Annual Meeting
 

Development of PK-PD Models To Predict The Therapeutic Dose And CNS Disposition of SCYX-7158 In The Treatment Of Stage 2 Human African Trypanosomiasis
October 23-26, 2010
Beijing, China

8th Annual Congress of International Drug Discovery Science and Technology
 

Discovery of Novel Benzoxaboroles as a New Class of b-Lactamase Inhibitors
September 12-15, 2010
Boston, MA

2010 Interscience Conference on Antimicrobial Agents and Chemotherapy
 

Discovery and Mechanism of Action of AN3365: A Novel Boron-containing Antibacterial Agent in Clinical Development for Gram-negative Infections

Potency and Spectrum of Activity of AN3365, a Novel Boron-containing Protein Synthesis Inhibitor, Tested against Enterobacteriaceae

Potency and Spectrum of Activity of AN3365, a Novel Boron-containing Protein Synthesis Inhibitor, Tested against Non-fermentative Gram-negative Bacilli

In Vitro Activities of AN3365: A Novel Boron Containing Protein Synthesis Inhibitor, and Other Antimicrobial Agents against Anaerobes and Neisseria gonorrhoeae.

Murine Pharmacokinetics and In Vivo Gram-negative Activity of AN3365, A Novel Boron-containing Protein Synthesis Inhibitor.

AN3365 (GSK2251052): a Novel Boron Antibiotic for the Treatment of Multidrug-resistant Gram-negative Bacterial Infections
August 15-20, 2010
Melbourne, Australia

The XIIth International Congress of Parasitology
 

Novel Boron-Containing Small Molecules Demonstrate Potent Activity Against Trypanosoma cruzi
June 13-18, 2010
Waterville Valley, NH

Gordon Conference on Cyclic Nucleotide Phosphodiesterases
 

A Series of Potent Orally-Available Benzoxaborole PDE4 Inhibitors which Gain Potency by use of Novel Contacts Within the PDE4 Active Site
April 28-29, 2010
San Diego, CA

HCV Drug Discovery 5th CHI Conference
 

Boron and non-boron HCV NS3/4 protease inhibitors: new motifs with high potency against PI-resistant mutants
March 21-25, 2010
San Francisco, CA

American Chemical Society 239th National Meeting
 

Design, Synthesis and SAR of a-Amino Cyclic Boronate-containing Macrocyclic Inhibitors of HCV NS3/4A Serine Protease

Acyclic HCV NS3/4A Serine Protease Inhibitors with Benzoxaborole at P4 Position: Design, Synthesis and SAR

Synthesis and Evaluation of Novel Inhibitors Containing P1’ Benzoxaborole for HCV NS3/4A Serine Protease

Macrocyclic HCV NS3/4A Serine Protease Inhibitors with Benzoxaborole at P4 Position: Design, Synthesis and SAR
February 14-19, 2010
Santa Fe, NM

Keystone Symposia: Antibiotics and Resistance: Challenges and Solutions
 

Structure-guided discovery of ABX a 3-Aminomethyl Benzoxaborole: A first in class Antibacterial for Gram-negative Bacterial Infections
January 28-29, 2010
La Jolla, CA

8th Annual Cytokines and Inflammation Conference
 

AN6415: A Novel, Highly Potent, PDE4 Inhibitor with Oral Activity and Broad Spectrum Cytokine Suppression
January 25–27, 2010
Philadelphia, PA

Anti-Infectives Summit
 

Structure-Guided Discovery of (S)-3- (aminomethyl)benzo[c][1,2]oxaborol- 1(3H)-ol hydrochloride (ABX): A First in Class Gram-negative Antibacterial
November 20, 2009
Washington, DC

The American Society of Tropical Medicine and Hygiene
 

Novel Boron-Containing Small Molecules Demonstrate Potent Activity Against Malaria Parasites with Excellent Drug-like Properties.

Novel Boron-Containing Small Molecules as Potential Therapeutics Against Human Lymphatic Filariasis
October 22-25, 2009
Shanghai, China

7th Annual Congress of International Drug Discovery Science and Technology

 

Novel Cyclic Boronates as HCV NS3/4A Protease Inhibitors
September 12-15, 2009
San Francisco, CA

Interscience Conference on Antimicrobial Agents and Chemotherapy Conference
 

F1-1223a: In Vitro Activity and In Vivo Efficacy of (S)-3(aminomethyl)benzo[c] [1,2]oxaborol-1(3H)-ol (ABX): A Gram-negative Antimicrobial
August 16-20, 2009
Washington, DC

American Chemical Society
 

Lead Optimization Investigation of Oxaboroles for the Treatment of Human African Trypanosomiasis
July 6-10, 2009
Tokyo, Japan

World Congress of Inflammation
 

P339

Discovery of Novel Boron Containing Compounds as Dual Inhibitors of TNF-a and IL-23 Release
May 31 - June 4, 2009
Philadelphia, PA

American Society for Mass Spectrometry 57th Annual Conference
 

P1046

A Direct LC/MS/MS Method to Determine the Amount of Ciclopirox Penetrated Across Human Nail Plate in In Vitro Penetration Studies
May 6-9, 2009
Montreal, Canada

Society for Investigative Dermatology Annual Meeting
 

P282

Structure-Activity Studies Led To The Discovery Of AN2898 In Development For Topical Treatment Of Psoriasis And Atopic Dermatitis
March 22-26, 2009
Breckenridge, CO

Key Stone Symposium
 

Novel Oxaborole 6-Carboxamides Demonstrate Potential for Treatment of CNS-Stage Human African Trypanosomiasis
March 6-10, 2009
San Francisco, CA

The American Academy of Dermatology Annual Meeting
 

P1317

Structure-Activity Studies Led To The Discovery Of AN2898 In Development For Topical Treatment Of Psoriasis And Atopic Dermatitis

P1318

AN2898 Inhibits Cytokines Relevant to Topical Treatment of Psoriasis and Atopic Dermatitis

P2422

AN2718 has Broad Spectrum Antifungal Activity Necessary for the Topical Treatment of Skin and Nail Fungal Infections

P3327

AN2728 Demonstrates Significant Efficacy in Three Phase Ib Psoriasis Microplaque Trials

P3328

AN2728 Demonstrates Significant Safety and Efficacy in a Phase IIa Double Blind Trial in Plaque Type Psoriasis

P3357

AN2728 Preclinical Studies Demonstrate An Acceptable Safety Profile For The Topical Treatment Of Psoriasis And Atopic Dermatitis
December 7-11, 2008
New Orleans, LA

American Society of Tropical Medicine and Hygiene
 

A New Class of Benzoxaborole-based Potent Antitrypanosomal Agents: Probing the Effect of Different Linkage Groups on Trypanosoma brucei Growth Inhibition

AN2920, A Novel Oxaborole, Shows In Vitro and In Vivo Activity Against Trypanosoma brucei.

A Novel Oxaborole, AN3520, Shows Efficacy Against Human African Trypanosomiasis (HAT) In Vitro and In Vivo, Including Promise in a Murine CNS Model of T. brucei Infection
October 25-28, 2008
Washington D.C.

48th Interscience Conference on Antimicrobial Agents and Chemotherapy
 

FI-1176

Antifungal Activity and Mechanism of Action of a Benzoxaborole, AN2718, which is in Development for the Treatment of Tinea Pedis
October 2-6, 2008
Gleneden Beach, Oregon

Montagna Symposium on the Biology of Skin
 

PSR-102

AN2728 Ointment, A Novel Oxaborole With Anti-Inflammatory Activity, Demonstrates Safety and Significant Efficacy in a Phase Ib Psoriasis Plaque Test
May 14-18, 2008
Kyoto, Japan

International Investigative Dermatology Conference
 

P84

Preclinical toxicology of AN2728, a novel oxaborole in development for the topical treatment of psoriasis

P86

AN2898, a novel oxaborole compound with anti-inflammatory activity: mechanism of action and in vitro cytokine inhibition

P88

Structure-activity studies of AN2728 and AN2898, novel oxaborole compounds with anti-inflammatory activity

P89

In vitro activity and mechanism of action of AN2728, a novel oxaborole in development for treatment of psoriasis.

P90

AN2898, a novel oxaborole compound with anti-inflammatory activity: results of in vivo efficacy and preclinical safety studies

P367

AN2728, a novel oxaborole in development for treatment of psoriasis, demonstrates significant activity in a micro plaque study
Feb. 2 - 6, 2007
Washington, DC

American Academy of Dermatology, 65th Annual Meeting
 

P2756

Preclinical Toxicology of AN2728, A Novel Borinic Acid Ester with Anti-Inflammatory Activity

P406

AN0128 inhibits pro-inflammatory cytokine production in a macrophage cell line by inhibiting the p38 MAP kinase signal transduction pathway

P421

AN2728, A novel Oxaborole with broad-spectrum in-vitro anti-inflammatory activity

P717

A Randomized, Double-Blind, Vehicle-Controlled, Multi-Center Study to Evaluate the Safety and Efficacy of Topically Applied AN0128 1% Cream for the Treatment of Mild to Moderate Atopic Dermatitis

P1800

In vitro Nail Penetration Of AN2690, Effect Of Vehicle And Coefficient Of Efficacy

P1802

Interim Results of a Multi-Center Study to Evaluate the Safety and Efficacy of Topically Applied AN2690 5.0% and 7.5% Solutions for the Treatment of Onychomycosis of the Great Toenail

P1816

In vivo nail residence time of AN2690, a novel broad-spectrum antifungal agent in development for the topical treatment of onychomycosis

P1823

An Open-Label, Multiple-Dose Study of the Absorption and Systemic Pharmacokinetics of AN2690 Applied as a 7.5% Solution to All Toenails of Adult Patients with Moderate to Severe Onychomycosis

P2703

Medicinal Chemistry Development Of AN2728, A Novel Oxaborole In Development For The Topical Treatment Of Psoriasis

P2712

Skin Penetration And Anti-Inflammatory Activity of AN2728, A Novel Oxaborole
Oct. 29 - Nov. 2, 2006
San Antonio, TX

American Association of Pharmaceutical Scientists, Annual Meeting

Nail Penetration and Nail Concentration of AN2690, a Novel Broad-spectrum Antifungal Agent in Development for the Topical Treatment of Onychomycosis
Oct. 1 - 6, 2006
San Diego, CA

2006 International Conference on Aminoacyl-tRNA synthetases: From the Genetic Code to Human Diseases & Medicine

A new class of leucyl-tRNA synthetase inhibitors: targeting the editing domain
Sept. 10 - 14, 2006
San Francisco, CA

232nd ACS National Meeting
 

Medi332

Discovery and SAR of Diphenylborinic Acid Picolinate Esters as A Potent Antibacterial and Anti-inflammatory Agent for the Treatment of Skin Diseases
Sept. 7 - 9,2006
Paris, France

European Society For Dermatological Research, 36th Annual Meeting
 

P91

Nail Penetration Of AN2690: Efficacy Coefficient And Effect of Formulation

P94

New AN0128 Formulations Improve In Vitro Skin Penetration and In Vivo Efficacy

P346

AN0128 Inhibits Pro-inflammatory Cytokine Production in a Macrophage Cell Line by Inhibiting the p38 MAP Kinase Signal Transduction Pathway

P565

Interim Results of a Multi-Center Study to Evaluate the Safety and Efficacy of Topically Applied AN2690 5.0% and 7.5% Solutions for the Treatment of Onychomycosis of the Great Toenail

P566

An Open-Label, Multiple-Dose Study of the Absorption and Systemic Pharmacokinetics of AN2690 Applied as a 7.5% Solution to All Toenails of Adult Patients with Moderate to Severe Onychomycosis

P567

A Randomized, Double-Blind, Vehicle-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of Topically Applied AN0128 1% Cream for the Treatment of Mild to Moderate Atopic Dermatitis
May 3-6, 2006
Philadelphia, PA

Society for Investigative Dermatology, 67th Annual Meeting
 

P750

In vitro Nail Penetration Profile Of AN2690, A Novel Broad-Spectrum Antifungal Agent In Development For The Topical Treatment Of Onychomycosis

P769

AN2690, a topical antifungal agent in development for the treatment of onychomycosis represents a new class and has a novel mechanism of action

P775

Medicinal Chemistry Of AN2690, A Novel Broad-Spectrum Antifungal Agent In Development For The Topical Treatment Of Onychomycosis
April 19, 2006
La Grande Motte, France

Perspectives in Percutaneous Penetration (PPP), 10th International Conference

Human Nail Penetration Of AN2690, A New Antifungal Agent In Development For The Topical Treatment Of Onychomycosis
March 3 - 7, 2006
San Francisco, CA

American Academy of Dermatology, 64th Annual Meeting
 

P103

A Novel Borinic Acid Ester With Antibacterial Activity Against Propionibacterium acnes

P104

A Novel Synthetic Borinic Acid Ester with a Broad Spectrum of Antibacterial Activity

P108

AN0128, A Novel Borinic Acid Ester with In Vitro and In Vivo Anti-Inflammatory Activity

P122

Preclinical Toxicology of AN0128, A Novel Borinic Acid Ester with Combined Antimicrobial and Anti-Inflammatory Activity

P145

Clinical Safety of AN0128, a Novel Borinic Acid Ester

P800

A Novel Borinic Acid Ester with Antibacterial Activity Against Staphylococcus aureus

P1607

Initial Characterization of Resistant Mutants to AN2690, A New Antifungal Agent in Development for the Topical Treatment of Onychomycosis, Predicts a Novel Mechanism of Action

P1608

Microbiological Activity of AN2690, a New Antifungal Agent in Development for the Topical Treatment of Onychomycosis

P1611

Preclinical Toxicology of AN2690, A New Antifungal Agent in Development for the Topical Treatment of Onychomycosis


 

For media inquiries please email media@anacor.com.
spacer
 

SITEMAP | CONTACT | PRIVACY POLICY | TERMS OF USE | HOME

  
 

© 2011 Anacor Pharmaceuticals, Inc., All Rights Reserved.